Information Provided By: 
Fly News Breaks for December 2, 2019
AZN
Dec 2, 2019 | 08:11 EDT
Cowen analyst Steve Scala raised his price target on AstraZeneca to $55 from $48 as he believes its product momentum and high relative growth are not recognized. The analyst believes there is opportunity for upside as forecasts are below the company's guidance and its low relative exposure to the U.S. makes it less vulnerable to election rhetoric. Scala reiterated his Outperform rating on AstraZeneca shares.
News For AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
Apr 25, 2024 | 05:49 EDT
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
